Aslan picks up preclinical A*STAR antibody

Aslan Pharmaceuticals Pte. Ltd. (Singapore) acquired worldwide rights from Singapore's Agency for Science, Technology and Research (A*STAR) to a preclinical antibody targeting macrophage stimulating 1 receptor c-Met-related tyrosine kinase ( MST1R; RON; CD136).

A*STAR will be responsible for preclinical development under a three-year research collaboration with Aslan, which said the candidate has shown efficacy "in a range" of in vivo cancer models. Aslan will be responsible for designing clinical studies, which it expects to start in 2018. ...